Meridian Venture Partners is privately backed UK venture capital firm focused on investing and working with development stage technology businesses, primarily based in the UK.
We are actively engaged with all our investment companies. This means we like to keep up-to-date with the latest developments so we can discuss operational and strategic issues when needed - not just at board meetings. It also means that we communicate effectively amongst our team so that the person with the most appropriate skills is kept up to speed.
Our team offers experience ranging from sales and marketing through to financing, primarily focused towards companies in the development stage. This helps us to address the most common issues.
We invest time in our executive management relationships. We believe that open lines of communication empower management to build large & valuable companies.
We do this because we've been involved in development stage companies and we want to be part of creating innovative and valuable companies.
|Mar, 2012||PeerIndex||$3M / Series A (Lead)||Mitchell Pender|
|May, 2011||Cognitive Match||$6M / Series C (Lead)||Mitchell Pender|
|Jul, 2008||i-nexus||$4M / Venture (Lead)||Kevin Douglas|
|Jun, 2008||i-nexus||$2M / Series A||Kevin Douglas|
|Jun, 2008||CommonTime||$1M / Series A||—|
|May, 2002||Index Stock Imagery||$4.5M / Venture (Lead)||—|
|Oct, 2001||ExpertPlan||$4M / Series A||—|
|Mar, 2001||Planalytics (B2B)||$15M / Venture||—|
|Dec 17, 2014||Tech.eu - Brandwatch acquires London-based PeerIndex|
|May 28, 2014||TechCrunch - Retargetting Startup Cognitive Match Acquired By Magnetic|
|May 28, 2014||TechCrunch - Retargetting Startup Cognitive Match Acquired by Magnetic|
|May 18, 2011||TechCrunch - Cognitive Match Secures $6 Million For Ad Targeting Technology|
|May 9, 2011||i-nexus.com - i-nexus|
|May 9, 2011||commontime.com - CommomTime|
|Apr 16, 2004||PE HUB - PE Week Wire -- Friday 4/16|
|Apr 12, 2004||Business Wire - Meridian Venture Partners Funds Buy-Out of Liquids Pharmaceutical Company; New CEO to Transform the Company into Specialty Pharmaceutical Player|
13/14 Great Saint Thomas Apostle
London, England EC4V 2BB